Financials
Financial year 2024
Papillon Pharmaceutical Solutions from Gent, company number BE0679971582, closed financial year 2024 with a result of € 203,271 after tax. For that financial year Papillon Pharmaceutical Solutions recorded a gross margin of € 294,717 and equity of € 1.5 million. Compared with financial year 2023, the result moved from € 258,970 to € 203,271. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2025.
€ 1.5 million
▲ 15% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 203,271
▼ 22% vs 2023
Profit after tax over the fiscal year.
€ 331,733
▼ 46% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 1.5 million.
People and assets in 2024
€ 75,704
▼ 20% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 30,193
▼ 13% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 106,005
▲ € 82,019 vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 409,071 | € 452,613 | € 388,833 | € 294,717 | ▼ 24% |
| Profit after taxes | € 264,235 | € 302,415 | € 258,970 | € 203,271 | ▼ 22% |
| Equity | € 764,601 | € 1,067,015 | € 1,325,985 | € 1,529,256 | ▲ 15% |
| Total debts | € 289,586 | € 171,974 | € 58,816 | € 136,198 | ▲ 132% |
| Cash | € 558,867 | € 644,095 | € 610,153 | € 331,733 | ▼ 46% |
| Land & buildings | - | - | € 4,353 | € 3,907 | ▼ 10% |
| Retained profit | € 752,201 | € 1,054,615 | € 1,313,585 | € 1,516,856 | ▲ 15% |
| Bank debt | € 15,684 | € 3,941 | € 0 | € 0 | |
| Balance sheet total | € 1,054,187 | € 1,238,989 | € 1,384,801 | € 1,665,455 | ▲ 20% |
Key figures of Papillon Pharmaceutical Solutions, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Papillon Pharmaceutical Solutions?
What happened at Papillon Pharmaceutical Solutions in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 203,271 (▼ 22% vs 2023). filed late Source: NBB ↗
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 264,235 profit in 2021 to € 203,271 profit in 2024.
Paid € 485,937 in corporate taxes since 2021.
Best year ever: 2022, with € 302,415 profit.
Management
Behind Papillon Pharmaceutical Solutions is Mario Papillon.
Directors
According to the 2024 annual accounts
Mario Papillon
Director
Establishments
Establishment units
Physical locations of this company
Edmond Boonenstraat 6
9000 Gent
Predikherenlei 1
9000 Gent
Active since 23 August 2017
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0679.971.582
- VAT number
- BE 0679.971.582
- Registered office
- Edmond Boonenstraat 6, 9000 Gent
- Names & denominations
- Papillon Pharmaceutical Solutions
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 August 2017
- Peppol
- Active · Active since 1 Jan 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering